Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Prelude Therapeutics Incorporated (PRLD) had Weighted-Average Shares Outstanding (Diluted) of 76.13M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$6.50M |
|
$-19.73M |
|
-- |
|
$6.50M |
|
$26.92M |
|
$-20.42M |
|
$0.69M |
|
$-19.73M |
|
$-19.73M |
|
$-19.73M |
|
$-19.73M |
|
$-19.73M |
|
$-19.73M |
|
$-20.42M |
|
$-20.04M |
|
76.13M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
76.13M |
$-0.26 |
|
$-0.26 |
|
| Balance Sheet Financials | |
$58.33M |
|
$5.53M |
|
$36.42M |
|
$94.75M |
|
$18.19M |
|
-- |
|
$18.03M |
|
$36.22M |
|
$58.53M |
|
$58.53M |
|
$58.53M |
|
56.60M |
|
| Cash Flow Statement Financials | |
$-79.42M |
|
$113.80M |
|
$-0.13M |
|
$16.52M |
|
$50.77M |
|
$34.25M |
|
$10.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-314.12% |
|
-314.12% |
|
-- |
|
-303.46% |
|
-303.46% |
|
$-79.49M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
-- |
|
-- |
|
-- |
|
-33.70% |
|
-33.70% |
|
-20.82% |
|
-33.70% |
|
$1.03 |
|
$-1.04 |
|
$-1.04 |
|